help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maness, L. M.
Right arrow Articles by Banks, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maness, L. M.
Right arrow Articles by Banks, W. A.
Endocrinology Vol. 139, No. 11 4556-4562
Copyright © 1998 by The Endocrine Society


ARTICLES

Fate of Leptin after Intracerebroventricular Injection into the Mouse Brain

Lawrence M. Maness, Abba J. Kastin, Catherine L. Farrell and William A. Banks

Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, Louisiana 70112-1262; the Department of Pathology, Amgen, Inc. (C.L.F.), Thousand Oaks, California 91320-1789; and Geriatric Research Educational and Clinical Center (GRECC), Veterans Administration Medical Center-St. Louis (W.A.B.) and the Division of Geriatrics, Department of Internal Medicine, Saint Louis University School of Medicine (W.A.B.), Saint Louis, Missouri 63106

Address all correspondence and requests for reprints to: Lawrence M. Maness, Ph.D., Veterans Affairs Medical Center, Research Service, 1601 Perdido Street, New Orleans, Louisiana 70112-1262. E-mail: lmaness{at}mailhost.tcs.tulane.edu


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The fate of the metabolic regulatory protein leptin was studied after intracerebroventricular (icv) administration into the lateral ventricle of the brain. In the brain, a mean of 72% of the recovered radioiodinated leptin was intact. Efflux from the brain for leptin occurred with the reabsorption of the cerebrospinal fluid into the blood. Leptin appearing in the blood was 71% intact over the course of the study. The amount of leptin in the blood rose slowly, and 20 min after icv injection equaled or exceeded levels previously seen 20 min after iv administration. Autoradiography showed the slow disappearance of leptin from the ventricular system over time. The degree of periventricular penetration of radiolabeled leptin also was determined. By 30 min, leptin was detected 600 µm from the midline, but computer-assisted image analysis showed that the amount of radioactivity had fallen to half the midline value by 300 µm. The concentration of leptin within the arcuate nucleus, previously observed after iv administration, was not seen after icv injection. High concentrations of leptin were found at the choroid plexus, suggesting the presence of leptin receptors on the brain side of the blood-cerebrospinal fluid barrier and within the lumen of the middle cerebral arteries.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
LEPTIN, also known as OB protein, has been shown to influence weight regulation and satiety (1, 2, 3, 4). The potent actions of the protein on complex feeding behaviors and global metabolism strongly suggest that leptin exerts these effects within the central nervous system (CNS). Indeed, leptin receptor messenger RNA and leptin receptors have been demonstrated within several regions of the brain, including the hypothalamus and choroid plexus (CP) (5, 6, 7). Leptin is produced in adipose tissue (4). Therefore, for peripherally produced leptin to regulate specific central activities, the protein must first gain access into the brain by penetrating the blood-brain barrier (BBB). In a previous study, we demonstrated the insulin-independent saturable transport of radioiodinated leptin into the brain after iv administration in mice (8). Furthermore, the study also identified the arcuate nucleus of the hypothalamus as a specific target of the transported protein.

In experimental procedures, leptin is often delivered directly into the brain of rodents and small mammals by intracerebroventricular (icv) injection, bypassing the BBB transport event. Such an approach quickly delivers large quantities of leptin to the brain and may lower the risk of enzymatic degradation. However, the dynamics of movement within the brain vary significantly from compound to compound (9) and must be taken into account to accurately assess physiological and pharmacological properties of icv administered materials.

Delivery of exogenous leptin to the ventricular system may mimic the hypothesized transport of the blood-borne protein by the CP (7). The subsequent kinetics of distribution after either mechanism of penetration also could be quite comparable. However, the fate of leptin after icv injection has not been thoroughly described. Several possible paths are available subsequent to central injection. The protein may distribute quickly throughout the brain, leading to numerous physiological effects. It is also possible that the protein would be restricted to the ventricular space and be subject to dispersion and removal by the flow of the cerebrospinal fluid (CSF). With CSF removal, leptin would enter the blood, raising the possibility of interactions with its receptor, including those found at the CP. In addition, the degree of degradation of icv administered leptin has not been fully detailed.

In the present study, we investigated the fate of radioiodinated leptin after icv administration in the mouse. The disappearance of leptin from the brain and the appearance of the protein in the blood were measured, and the degrees of intactness in both environments were assessed over time. Furthermore, to determine the degrees of penetration of radioiodinated leptin into the tissues surrounding the ventricular system, we applied film autoradiography to mouse brain sections after icv injection. A similar autoradiographic approach was used to quantify the amount of radioiodinated leptin localized to several regions believed to be involved in the physiological events triggered by leptin.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Iodination
Recombinant murine or human leptin was radioiodinated by incubation of 10 µg leptin (Amgen, Inc., Thousand Oaks, CA) with 2 mCi 125I and Enzymobead reagent (Bio-Rad, Richmond, CA) 24 h at 4 C. Radioactively labeled leptin (I-Lep) was isolated on a Sephadex G-10 minicolumn. I-Lep was diluted in lactated Ringer’s solution containing 1% BSA (LR-BSA) and stored frozen at -70 C until use. The specific activity of I-Lep, as previously reported (8), was 103 Ci/g.

icv injection
Adult male ICR mice (Charles River Laboratories, Inc., Wilmington, MA), 20–25 g, were anesthetized with ip urethane (4.0 g/kg). For each mouse, the skull was exposed, and the bregma was located. A guarded 26-gauge needle was used to punch a hole 0.2 mm caudal to the bregma and 1.0 mm lateral to the midline at a depth of 2.25 mm. A 1.0- or 5.0-µl Hamilton syringe (Hamilton, Reno, NV) was used to inject specified quantities of murine or human I-Lep in a volume of about 1.0 µl into the right cerebral ventricle.

HPLC
About 5 x 106 cpm I-Lep were injected icv at time zero. Whole blood from the carotid artery and the whole brain was removed 2, 5, 10, 20, or 30 min after the icv injection. The blood was centrifuged at 4 C for 10 min at 5000 x g, and the serum was collected and lyophilized. The entire brain was homogenized in 2 ml LR-BSA after removal of the pituitary and pineal. The homogenate was centrifuged for 10 min at 4 C at 5000 x g, and the resulting supernatant was lyophilized.

Processing controls were used to determine the amount of degradation that occurred during collection, homogenization, and lyophilization. About 105 cpm was added to the surface of a brain from a mouse that had not been injected with radioactivity and the brain processed as described above. For the serum processing control, about 105 cpm were added to the bottom of a tube before the collection of arterial blood from a mouse that had not received an injection of radioactivity. The blood was then processed as described above.

Brain and serum samples were reconstituted immediately before HPLC analysis with 0.6 ml distilled water with 0.1% trifluoroacetic acid (TFA), vigorously mixed, and centrifuged at 4 C for 15 min at 5200 x g. Of the resulting supernatant, 0.1 ml was injected onto a C4 protein column (Vydac, Hesperia, CA) and eluted with a gradient that linearly progressed from 90% of solution A (0.1% TFA in water) to 90% of solution B (0.1% TFA in acetonitrile) in 50 min, with fractions collected every minute. The levels of radioactivity in the fractions were determined, and the percentage of radioactivity eluting from the column that eluted in the position of I-Lep was calculated. The values for the brain and blood samples were corrected for processing degradation by dividing them by the values of the processing controls for brain (32.5%) and blood (48.1%).

Appearance in blood
Percentage of the injected dose. About 5 x 106 cpm I-Lep were injected icv into 15 mice. Blood from the carotid artery was collected 2, 5, 10, 20, or 30 min after the icv injection (n = 3 mice/time point). The blood was centrifuged at 4 C at 5000 x g for 10 min, and the level of radioactivity in serum was determined. The whole brain was collected, the pituitary and pineal were removed, and the level of radioactivity was measured. The levels of radioactivity were corrected by use of the factors determined above under HPLC. The results were expressed in two ways. First, the HPLC-corrected level of radioactivity in 1 ml serum was divided by the amount of radioactivity injected and multiplied by 100 to yield the percentage of icv injected radioactivity present in 1 ml serum (percentage per ml). Second, the HPLC values for radioactivity in brain and serum were used to calculate brain/serum ratios in units of milliliters per g.

Pharmacokinetics. The brain to blood efflux rate (Q; percentage per min) of I-lep was calculated by the equation: Q = P(Ke)Vd/(1 - e(-)Ket) (Eq I), where P is the percentage per ml at time t, Ke is the inverse of the half-time disappearance rate in minutes of I-Lep from serum after its iv injection multiplied by 0.693, Vd is the volume of distribution in milliliters, and t is time in minutes (10). The half-time of disappearance for I-Lep has been determined to be 5.46 min (to give a Ke of 0.127), and the volume of distribution has been determined to be 2.43 ml (8).

Autoradiography
Two, 10, or 30 min after icv injection of 6 x 105 cpm radioiodinated murine or human leptin (2.65 ng I-Lep/mouse), mice were decapitated, and the brains were carefully removed. The intact brains were quickly dipped in -30 C isopentane for 12 sec and moved to a bed of crushed dry ice for 10 min, turning once for even freezing. The brains were then wrapped in plastic and stored for 24 h at -70 C. Frozen brains were warmed to -15 C, coronally sliced at 20 µm, and mounted on gelatin-coated slides.

The mounted sections were desiccated for 24 h at 4 C. Upon warming to room temperature, the slides were put on Hyperfilm 3H (Amersham, Arlington Heights, IL) for 5 days. The film was then developed with D-19 developer (Eastman Kodak Co., Rochester, NY).

Computer-assisted image analysis
Relative optical densities (RODs) of the autoradiographic images were measured with an MCID image analysis system (Imaging Research, Inc., St. Catharines, Canada). The total area of diffusion from the third ventricle was determined from each image by the autoscan function of the image analyzer. Measurements of maximal lateral diffusion of I-Lep from the third ventricle were made at two defined regions: the level of the anterior hypothalamus, 1.0 mm dorsal to the ventral base of the brain, and the level of the medial arcuate nucleus, 0.5 mm dorsal to the ventral base of the brain. For each time point, mean diffusion distances were determined, and the relationship was analyzed by one-way ANOVA and the Newman-Keuls multiple comparison test.

D1/2 values, the distance at which the amount of radioactivity equaled half the midline value, also were determined for each time point. A sampling tool, 200 µm in height, was used to measure across the labeled regions at the same coordinates used to determine maximal lateral diffusion from the third ventricle. Transept lines generated from these measurements were then used to determine the distance from the midline/third ventricle needed for the intensity of the labeling to decrease by half. The left and right hemisphere values for each transept line were averaged, and the mean distances of several serial sections were determined. The relationship of the D1/2 values was analyzed by ANOVA and Newman-Keuls multiple comparison test.

Other autoradiograms generated from the 30-min exposure group were analyzed for degrees of labeling at the arcuate nucleus, a region of the brain previously shown to accumulate I-Lep after iv administration (8). ROD values at the arcuate nucleus were compared statistically to other areas labeled by icv I-Lep, including the CP, third ventricle periventricular tissue, and the middle cerebral artery. The specific areas were delineated and measured with templates created from the tissues used to generate the autoradiographic images. Measurements of ROD also were taken at the background of the autoradiographic film and used as correction factors. Multiple measurements were averaged and compared by ANOVA and Newman-Keuls posttests.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
HPLC
The percentages of radioactivity in brain and serum that eluted by HPLC as I-Lep are shown in Table 1Go. For brain, the percent of radioactivity representing I-Lep ranged from 58–85% over time. As there was no relation between time and percent intact, the values were combined over time to yield a mean of 72 ± 5% (n = 5). This value was used to correct levels of radioactivity in brain.


View this table:
[in this window]
[in a new window]
 
Table 1. Percentage of radioactivity in brain and serum samples eluting as intact I-Lep by HPLC at various times after icv injection

 
The percentage of radioactivity in serum samples eluting as I-Lep ranged from 44–97% between 5–30 min after icv injection. Because no correlation existed between the percentage of radioactivity and time, the values were combined for the times of 5–30 min to yield a mean of 71 ± 11.8%. This value was used to correct levels of radioactivity in serum for the time periods between 5–30 min. At 2 min, the value of 11% was markedly different from the other time points and may have reflected the efflux of free iodine, a substance rapidly transported from brain to blood by a saturable system (11) that may have been present in the icv injection of I-Lep. The value of 11% was used to correct levels of radioactivity obtained in serum at 2 min for the appearance in blood studies reported below.

Appearance in blood
Percentage of injected dose. Figure 1AGo shows the percentage of the icv injected I-Lep that appeared in 1 ml serum with time. The results were fitted to a second order polynomial equation: y = (-)0.00784x2 + 0.367x - 0.669, where y is percentage per ml, and x is time in minutes; the regression coefficient was 0.997. Based on this equation, the maximum value of 3.64%/ml occurred 23.4 min after icv injection. The brain/serum ratio in units of milliliters per g is shown in Fig. 1BGo.



View larger version (11K):
[in this window]
[in a new window]
 
Figure 1. Appearance of I-Lep in blood after icv injection. A, Percentage of icv injection appearing in 1 ml serum (percentage per ml) vs. time (minutes). The results were fitted to a second order polynomial equation: y = (-)0.00784x2 + 0.367x - 0.669. B, Brain/serum ratios (milliliters per g) vs. time (minutes).

 
Pharmacokinetics. Figure 2Go shows the efflux rate (Q) from brain based on the mean percentage per min values shown in Fig. 1AGo. Between 5 and 30 min, these values averaged 0.943 ± 0.126%/min (n = 4), showing that about 0.94% of the dose injected icv entered the blood each minute. This calculates to a half-time disappearance from brain of 73.1 min.



View larger version (9K):
[in this window]
[in a new window]
 
Figure 2. Efflux rate of leptin. The efflux rate (Q), in percentage per min, was calculated from the level of radioactivity in serum after the icv injection of I-Lep by the use of Eq I. The mean efflux rate for the times of 5–30 min was 0.943%/min.

 
Autoradiography and image analysis
The resulting autoradiographic images showed similar patterns of radioactivity distribution at the earlier time points. Two or 10 min after administration of I-Lep, the signal was generally restricted to the lateral and third ventricles (Fig. 3Go, A and B, and Fig. 4Go, A and B). Subtle degrees of penetration of radiolabeled material from the ventricular space into the surrounding tissues were observed at 10 min, but the majority of the labeling appeared to remain ventricular. However, by 30 min post-icv injection, a different pattern had emerged (Figs. 3CGo and 4CGo). A much greater degree of penetration was now evident within the periventricular tissues. The overall intensity of the radioactive labeling also was considerably lower than that at the shorter exposure times within both the periventricular and ventricular spaces.



View larger version (85K):
[in this window]
[in a new window]
 
Figure 3. Periventricular penetration of I-Lep at the level of the anterior hypothalamus after icv administration. Microautoradiographic images detailing the presence of I-Lep within the third ventricle and in the periventricular tissue 2 (A), 10 (B), and 30 (C) min after injection into the lateral ventricle. Horizontal bars spanning the highlighted areas represent the site used for the measurement of maximal lateral diffusion of I-Lep 1.0 mm above the ventral base of the section, as determined by the image analyzer, as shown in Table 2Go. Scale bar = 200 µm.

 


View larger version (66K):
[in this window]
[in a new window]
 
Figure 4. Periventricular penetration of I-Lep at the level of the medial arcuate nucleus after icv administration. A, Intense labeling within the ventricular space and CP, but minimal penetration of the protein into the periventricular tissues 2 min after icv injection. B, After 10 min, the ventricular signal had diminished, and the degree of max imal lateral periventricular labeling was significantly wider. C, By 30 min after administration, negligible amounts of I-Lep were detected in the ventricular space, although some labeling remained at the CP. Periventricular diffusion again was significantly greater than that at the earlier time points. Horizontal bars spanning the highlighted areas represent the site used for the measurement of maximal lateral diffusion of I-Lep 0.5 mm above the ventral base of the section, as determined by the image analyzer, as shown in Table 3Go. Scale bar = 1.0 mm.

 
ANOVA of the mean maximal lateral diffusion distances from the third ventricle at both the level of the anterior hypothalamus and the medial arcuate nucleus revealed a significant relationship (F7,35 = 45.35; P < 0.0001). Newman-Keuls multiple comparison test analysis revealed several instances of significant differences in maximal lateral diffusion (Tables 2Go and 3Go). At the anterior hypothalamus, the degree of I-Lep penetration was significantly greater after 30 min than after 2 or 10 min. Additional significant differences were seen between 2 and 10 min circulation values. At the level of the medial arcuate nucleus, significant differences also were seen between penetration distances for all pairings of 2, 10, and 30 min circulation values. Murine and human I-Lep showed no significant differences in periventricular penetration at either the hypothalamus or the arcuate nucleus 30 min after icv injection.


View this table:
[in this window]
[in a new window]
 
Table 2. Lateral diffusion and D1/2 values for I-Lep at the level of the anterior hypothalamus

 

View this table:
[in this window]
[in a new window]
 
Table 3. Lateral diffusion and D1/2 values for I-Lep at the level of the medial arcuate nucleus

 
A significant relationship also was found with ANOVA of the mean D1/2 values from the third ventricle at the level of both the anterior hypothalamus and the medial arcuate nucleus (F7,34 = 11.88; P < 0.0001). However, Newman-Keuls multiple comparison test analysis revealed fewer significant differences among the individual D1/2 values than were seen for the maximal lateral diffusion distances (Tables 2Go and 3Go). At the level of the anterior hypothalamus, the 30 and 2 min D1/2 values were the only groups to display a statistically significant difference. At the level of the medial arcuate nucleus, the 30 and 2 min values also displayed a significant difference, as did the 30 and 10 min values.

After 30-min circulation periods, ROD values at the arcuate nucleus and all other central regions measured were significantly greater than the mean background RODs (F4,10 = 27.41; P < 0.01 for each). After being corrected for background, ANOVA of the ROD values showed a significant relationship (F3,8 = 8.163; P < 0.01). Newman-Keuls comparisons showed the ROD of the arcuate nucleus (0.178 ± 0.028) to be significantly lower than the RODs of the CP (0.389 ± 0.012; P < 0.01) and the middle cerebral arteries (0.345 ± 0.053; P < 0.05). ROD values corresponding to the tissue adjacent to the third ventricle were not significantly different from the values found at the arcuate nucleus (P > 0.05). The localization of I-Lep within the arcuate nucleus was not as concentrated after icv injection compared with that seen after iv administration of I-Lep (8).

The CP continued to display prominent I-Lep labeling even after the CSF was essentially cleared of the labeled protein (Fig. 5Go). Thirty minutes after icv injection into the ventricle, autoradiographic images showed the CP to be heavily labeled, although the ventricular space and the surrounding tissues were not above background levels. The labeling was similar to that seen at the CP after iv administration of I-Lep (8) and suggested I-Lep binding on the brain side of the blood-CSF barrier.



View larger version (145K):
[in this window]
[in a new window]
 
Figure 5. Labeling of the choroid plexus in the lateral ventricle. A, Photomicrograph showing lateral ventricle and CP. B, Despite the clearance of I-Lep from the ventricular space by CSF turnover at 30 min, the microautoradiograph shows dense localization upon a single frond of CP, indicating the presence of leptin-binding sites on the brain side of the blood-CSF barrier. Scale bar = 10 µm.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The degree of physiological or behavioral response that a centrally administered compound may elicit is dependent on several factors. These include delivery to relevant, responsive regions within the brain, delivery of sufficient quantities of intact material, and the ability of the compound to reach these areas before clearance from the brain. Leptin injected into the ventricular space of the brain must meet these criteria to affect feeding behaviors and overall metabolism. The present study investigates the fate of I-Lep within the mouse after icv delivery. Our findings show that intact I-Lep slowly penetrates the periventricular tissues surrounding the third ventricle. The intact protein also is removed slowly to the bloodstream with CSF reabsorption, with blood levels rising over time.

Levels of I-Lep within the brain after icv injection were always much higher than those previously seen after iv injection (8). However, the results also show that a measurable amount of the leptin administered icv enters the blood. At about 20 min, blood levels after icv injection were similar to those seen after iv injection (8). The rate of brain to blood efflux based on the rate of appearance of I-Lep in serum is consistent with a nonsaturable process such as reabsorption of CSF.

The HPLC results shown in Table 1Go give the percentage of radioactivity in brain and serum representing intact I-Lep after icv injection and show that it is stable for at least 30 min. This suggests that iodinated degradation products arising from the catabolism of I-Lep in brain and blood are cleared at about the same rate as I-Lep. The relatively high level of radioactivity that represents intact I-Lep aids in the accurate assessment of the fate of leptin after icv injection.

I-Lep reaches levels in each milliliter of serum equal to 3.64% of the injected dose 23.4 min after injection. This slow rise is explained by icv injections often having similar pharmacokinetic profiles as those of iv infusions (12). By comparison, I-Lep injected as an iv bolus can be calculated, based on the previously determined (8) volume of distribution of 2.43 ml and the previously determined half-time of disappearance of 5.46 min, to decrease from 41.1%/ml at time zero to 2.11%/ml by 23.4 min. Therefore, at time periods greater than about 20 min, blood levels achieved after an icv injection equal or even exceed those seen after an iv injection.

The brain/serum ratio for I-Lep after icv injection declined in a logarithmic manner to a value of about 10 ml/g at 30 min. By contrast, the brain/serum ratio after iv injection is usually measured at about 0.03 ml/g. Therefore, the brain/serum ratio is at least 300 times higher after icv injection than after iv injection. However, as shown in Figs. 3CGo and 4CGo, most of the radioactivity in the brain 30 min after icv injection is not evenly distributed throughout the brain but is concentrated in the periventricular areas.

The efflux rate from brain can be calculated based on the assumption that the efflux occurs over time and, therefore, is analogous to an iv infusion. The iv infusion rate (Q) needed to achieve a given level in the blood can be calculated if the volume of distribution in blood and the half-time disappearance rate from blood are known (see Eq I). Figure 2Go shows the values for Q computed from the percentage per ml values of Fig. 1AGo. The mean value of Q for times between 5 and 30 min was 0.943%/min. This gives a half-time disappearance from brain of 73.1 min, a rate consistent with entry into the circulation by reabsorption of CSF. Previous results based on the rate of disappearance of radioactivity from the CNS after icv injection gave a value of 53.7 min, a rate that was not statistically different from that of albumin, which exits the brain by being reabsorbed with the CSF (8). In that previous study, total levels of radioactivity were used and not levels corrected to reflect intact I-Lep only; if total radioactivity appearing in serum had been used here instead of corrected counts, the efflux rate would have yielded a half-time disappearance from brain of 53.0 min.

Computer-assisted analysis of the autoradiographic images provided both qualitative and quantitative evidence that after injection into the lateral ventricle of the brain, a measurable degree of I-Lep escapes the ventricular space and enters the periventricular tissue. Since ventricular flow can carry the CSF and CSF-borne I-Lep from the lateral ventricles to the third then to the fourth ventricles, with the fluid then entering the subarachnoid space, periventricular penetration into surrounding tissues may occur along this path. In this study, penetration of I-Lep from the third ventricle into the brain parenchyma was measured at the level of both the anterior hypothalamus and the medial arcuate nucleus. The degree of movement into the tissue was significantly greater with time, indicating time-dependent diffusion in the dispersion of the protein. Detectable amounts of I-Lep were seen over 200 µm from the ventricle-tissue interface after only 2 min and nearly 600 µm from the interface by 30 min. However, turnover of the CSF appeared to be concurrently working against penetration with the simultaneous removal of the protein by bulk flow, since the amount of I-Lep at the ventricular origin was greatly diminished at the later time points.

Lateral diffusion brings I-Lep deeper into periventricular tissue and increases the possibility of interactions of the polypeptide with leptin-sensitive regions within the brain. In this study, D1/2 values, the distances at which leptin-associated radioactivity equaled half the midline value, showed that the amount of protein penetrating the periventricular tissue rapidly decreased with increasing distance from the third ventricle. For example, at the level of the anterior hypothalamus, the concentration of I-Lep had fallen to half of the midline value by about 300 µm, although amounts of radiolabeled protein greater than background could be detected another 300 µm further into the periventricular tissue. Statistical analysis of the D1/2 values showed that only the longest circulation times resulted in D1/2 values significantly greater than those resulting from a short 2-min circulation. The increased time necessary for sufficient amounts of leptin to diffuse from the ventricular space into deeper regions of the brain also increases the possibility of degradation of the protein by endogenous enzymes. Furthermore, only a limited amount of time is available for leptin diffusion to occur due to the removal of the protein with the turnover of the CSF.

Delivery of icv administered leptin to physiologically relevant regions of the brain, therefore, requires that such targets be relatively close to a ventricular space or that relatively large amounts be given. One site that has been implicated in the actions of leptin and is in close proximity to the third ventricle is the arcuate nucleus. Binding studies have shown that the arcuate nucleus possesses a high concentration of leptin receptors, which may be involved in the satiety effects of the protein (6, 13). In a previous investigation, we found that blood-borne leptin is saturably transported into the brain and is selectively localized to the arcuate nuclei, as demonstrated by in vivo autoradiography (8).

The present icv study does not demonstrate the same degree of leptin association with the arcuate nucleus that was seen after iv administration. Although the autoradiographic signal of the arcuate nucleus 30 min after icv injection was significantly greater than background, the degree of labeling at the nucleus was not different from that in the periventricular tissues. This suggests that only minimal amounts of I-Lep were reaching the arcuate from the third ventricle and were not sufficient to selectively label the nucleus, and that the selective labeling of the arcuate nucleus previously seen after iv administration is likely to be due to selective transport by the BBB.

Two other structures did show degrees of labeling significantly different from that in the arcuate nucleus after icv administration. Both the CP and the middle cerebral arteries displayed ROD values significantly greater, not lower, than that in the arcuate nucleus. The substantial labeling of the CP could be anticipated, given the intimate association of the CSF with the fronds of the CP, as well as the previous findings that the CP is another central structure possessing a high concentration of leptin receptors (5, 6, 7). However, the labeling of the CP after icv administration was comparable to the dense labeling of the CP previously seen after iv administration of I-Lep. This suggests that leptin receptors are present on both the CSF and blood sides of the tightly joined choroid epithelial cells that comprise the blood-CSF barrier.

The high ROD values observed at the middle cerebral arteries probably reflect the presence of the labeled protein in the blood after its reabsorption with CSF. CSF flows through the ventricular system and into the subarachnoid space, where the fluid along with CSF-borne materials are removed to the venous circulation at the arachnoid granulations. Thirty minutes after icv injection of I-Lep, a substantial portion of the bolus would have been absorbed out of the ventricular system and into the peripheral circulation. Therefore, some of the radioactivity would be expected to be found in the lumen of the vessels of the cerebral vasculature.

Taken together, these findings show that leptin slowly exits the CNS by being reabsorbed with the CSF to enter the circulation. Due to this efflux, leptin can achieve measurable levels in the serum, where it would be available to stimulate peripheral receptors. Therefore, in designing icv experiments, consideration should be given to dose, time, and potency relative to that of the iv route of administration. Furthermore, the extent of penetration of icv administered leptin into the periventricular tissues also should be taken into account. In smaller animal models, minimal diffusion of leptin from the ventricular space may be sufficient to induce physiological effects. However, in species with the greatest brain mass, comparable degrees of penetration may not be adequate to trigger the anticipated responses.


    Acknowledgments
 
We thank Dr. Weitao Huang for technical assistance, and Melita Fasold for technical assistance and manuscript preparation.

Received January 29, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P 1995 Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269:546–549[Abstract/Free Full Text]
  2. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F 1995 Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543[Abstract/Free Full Text]
  3. Weigle DS, Bukowski TR, Foster DC, Holderman S, Kramer JM, Lasser G, Lofton-Day CE, Prunkard DE, Raymond C, Kuijper JL 1995 Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 96:2065–2070
  4. Zhang Y, Proenca R, Maffel M, Barone M, Leopold L, Friedman JM 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432[CrossRef][Medline]
  5. Malik KF, Young WS, III 1996 Localization of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57BL/6J mice. Endocrinology 137:1497–1500[Abstract]
  6. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Trayhurn P 1996 Localization of leptin receptor mRNA and the long form splice varient (ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett 387:113–116[CrossRef][Medline]
  7. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir, C, Sanker, S, Moriarty, A, Moore, KJ, Smutko, JS, Mays, GG, Woolf, EA, Monroe, CA, Tepper, RI 1995 Indentification and expression cloning of a leptin receptor, OB-R. Cell 83:1263–1271[CrossRef][Medline]
  8. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM 1996 Leptin enters the brain by a saturable system independent of insulin. Peptides 17:305–311[CrossRef][Medline]
  9. Maness LM, Banks WA, Zadina JE, Kastin AJ 1996 Periventricular penetration and disappearance of icv Tyr-MIF-1, DAMGO, tyrosine, and albumin. Peptides 17:247–250[CrossRef][Medline]
  10. Greenblatt DJ, Koch-Weser J 1975 Clinical pharmacokinetics. N Engl J Med 293:702–705[Medline]
  11. Reed DJ, Woodbury DM, Jacobs L, Squires R 1965 Factors affecting distribution of iodide in brain and cerebrospinal fluid. Am J Physiol 209:757–764[Abstract/Free Full Text]
  12. Davson H, Welch K, Segal MB 1987 The return of cerebrospinal fluid to the blood: the drainage mechanism. In: The Physiology and Pathophysiology of the Cerebrospinal Fluid. Churchill Livingstone, Edinburgh, pp 485–521
  13. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG 1996 Identification of targets of leptin action in the rat hypothalamus. J Clin Invest 98:1101–1106[Medline]



This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
M. Fry, T. D. Hoyda, and A. V. Ferguson
Making Sense of It: Roles of the Sensory Circumventricular Organs in Feeding and Regulation of Energy Homeostasis
Experimental Biology and Medicine, January 1, 2007; 232(1): 14 - 26.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. M. Penn, L. C. Jordan, E. W. Kelso, J. E. Davenport, and R. B. S. Harris
Effects of central or peripheral leptin administration on norepinephrine turnover in defined fat depots
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1613 - R1621.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. B. Goralski, D. Abdulla, C. J. Sinal, A. Arsenault, and K. W. Renton
Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS inflammation
Am J Physiol Gastrointest Liver Physiol, September 1, 2005; 289(3): G434 - G443.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. M. Ogilvie, R. Saladin, T. R. Nagy, M. S. Urcan, R. A. Heyman, and M. D. Leibowitz
Activation of the Retinoid X Receptor Suppresses Appetite in the Rat
Endocrinology, February 1, 2004; 145(2): 565 - 573.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M. Amstalden, M.R. Garcia, R.L. Stanko, S.E. Nizielski, C.D. Morrison, D.H. Keisler, and G.L. Williams
Central Infusion of Recombinant Ovine Leptin Normalizes Plasma Insulin and Stimulates a Novel Hypersecretion of Luteinizing Hormone after Short-Term Fasting in Mature Beef Cows
Biol Reprod, May 1, 2002; 66(5): 1555 - 1561.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
A. J. Kastin, M. B. Fasold, and J. E. Zadina
Endomorphins, Met-Enkephalin, Tyr-MIF-1, and the P-glycoprotein Efflux System
Drug Metab. Dispos., March 1, 2002; 30(3): 231 - 234.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. A. Banks, S. A. Farr, M. E. La Scola, and J. E. Morley
Intravenous Human Interleukin-1alpha Impairs Memory Processing in Mice: Dependence on Blood-Brain Barrier Transport into Posterior Division of the Septum
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 536 - 541.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
B. V. Zlokovic, S. Jovanovic, W. Miao, S. Samara, S. Verma, and C. L. Farrell
Differential Regulation of Leptin Transport by the Choroid Plexus and Blood-Brain Barrier and High Affinity Transport Systems for Entry into Hypothalamus and Across the Blood-Cerebrospinal Fluid Barrier
Endocrinology, April 1, 2000; 141(4): 1434 - 1441.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. G. Hohmann, T. H. Teal, D. K. Clifton, J. Davis, V. J. Hruby, G. Han, and R. A. Steiner
Differential role of melanocortins in mediating leptin's central effects on feeding and reproduction
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2000; 278(1): R50 - R59.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Chen and S. Reichlin
Mechanisms by Which Blood Levels of Interleukin-6 (IL-6) Are Elevated after Intracerebroventricular Injection of IL-1{beta} in the Rat: Neural Versus Humoral Control
Endocrinology, December 1, 1999; 140(12): 5549 - 5555.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. J. Kastin and V. Akerstrom
Entry of CART into brain is rapid but not inhibited by excess CART or leptin
Am J Physiol Endocrinol Metab, November 1, 1999; 277(5): E901 - E904.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
S. Lee, C. K. Kim, and C. Rivier
Nitric Oxide Stimulates ACTH Secretion and the Transcription of the Genes Encoding for NGFI-B, Corticotropin-Releasing Factor, Corticotropin-Releasing Factor Receptor Type 1, and Vasopressin in the Hypothalamus of the Intact Rat
J. Neurosci., September 1, 1999; 19(17): 7640 - 7647.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Z.-W. Wang, Y.-T. Zhou, T. Kakuma, Y. Lee, M. Higa, S. P. Kalra, M. G. Dube, P. S. Kalra, and R. H. Unger
Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia
PNAS, August 31, 1999; 96(18): 10373 - 10378.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Reichlin
Editorial: Is Leptin a Secretion of the Brain?
J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2267 - 2269.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Wiesner, M. Vaz, G. Collier, D. Seals, D. Kaye, G. Jennings, G. Lambert, D. Wilkinson, and M. Esler
Leptin Is Released from the Human Brain: Influence of Adiposity and Gender
J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2270 - 2274.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maness, L. M.
Right arrow Articles by Banks, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maness, L. M.
Right arrow Articles by Banks, W. A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals